Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(2):227-235. Importantly, existing data suggest a need for further pharmacoeconomic studies, given the limitations with existing economic studies as ...

This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma. Part 1 ...

The Standing National Committee on Medicines (SNCM) for revision of National List of Essential Medicines felt the need for capacity building for pharmacoeconomics as a discipline in India. The same is ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. A Leerink Center for Pharmacoeconomics (CPE) Exclusive ...

China has established itself as a frontrunner in pharmaceutical economics, supported by a network of more than 1,000 specialists advancing medical technology evaluations and regulatory innovations.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Facing constrained budgets and rising incidence of cancer, Egypt has established a specialist oncology committee and is taking steps towards value-based pricing for drugs. Islam Anan considers the ...